Русский
Venous thrombosis and malignant gynecological diseases: the place of direct oral anticoagulants in prevention
DOI: https://dx.doi.org/10.18565/pharmateca.2023.11.20-23
E.A. Ulrikh
1) Almazova National Medical Research Center, St. Petersburg, Russia; 2) Petrov National Medical Research Center of Oncology, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia
Venous thromboembolism (VTE) is a common but preventable cause of death in women after surgery for gynecological cancer. the use of unfractionated heparins or low molecular weight heparins for a month is the standard of thromboprophylaxis after major abdominal and pelvic surgery for malignant neoplasms. Direct oral anticoagulants (DOACs) are approved for the treatment of VTE in the general population. This regimen has significant advantages over other types of anticoagulant regimens, in particular the oral administration without the need for laboratory monitoring. The review presents the benefits of using DOACs based on updated information from completed and ongoing clinical trials.
Keywords: direct oral anticoagulants, gynecological cancer, thrombosis, anticoagulants, venous thromboembolism
About the Autors
Corresponding author: Elena A. Ulrikh, Dr. Sci. (Med), Prof., Almazov National Medical Research Center; Petrov National Medical Research Center of Oncology, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; rectorat@szgmu.ru; ORCID: https://orcid.org/0000-0002-2701-8812
Similar Articles
